PolyPid Ltd.

NASDAQ:PYPD

Biotechnology

Healthcare
$6.56 +8.23%

+$0.39 today

Market cap
$133.25M
Beta
1.43
P/E (TTM)
-2.7
EPS (TTM)
-$1.53
52W Low $3.06High $5.21

Volume 0.30M

Average 0.09M

PYPD EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

PolyPid Ltd.NASDAQ: PYPD

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$7.73M, compared with -$7.58M a year earlier. Trailing-twelve-month EBITDA was -$32.68M.

Context

  • EBITDA grew in size in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 2 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -23.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$7.73M+4.9% QoQ
Last fiscal yearDec 2025
-$31.86M-23.3% YoY
LTMMar 2026
-$32.68M-11.5% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.0%+100.0%+102.0 pp
1 year-23.3%+100.0%+123.3 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(31.86M) USD
Year-over-year change
-23.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How PYPD compares with its peers on the latest reported figures

  • PYPD's LTM Mar 2026 EBITDA of -$32.68M is the 5th highest of the 7 companies compared; the peer median is -$27.97M.
  • Its year-over-year change of -11.5% is the 4th highest of 7, against a peer median of -17.5%.
PYPD Competitors Peer median
EBITDA for PYPD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$12.18M +130.3%—34.7%
MAIAMAIA Biotechnology, Inc.LTM Mar 2026-$14.89M -54.8%——
PDSBPDS Biotechnology CorporationLTM Mar 2026-$27.92M +15.6%——
VERUVeru Inc.LTM Mar 2026-$28.02M +27.0%——
PYPDPolyPid Ltd.LTM Mar 2026-$32.68M -11.5%——
ANVSAnnovis Bio, Inc.LTM Mar 2026-$40.92M -50.5%——
CELUCelularity Inc.LTM Dec 2025-$77.62M -86.2%—292.4%
Peer median (excluding PYPD) -$27.97M-17.5%—163.5%

Competitors are the stored peer set for PYPD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue1.12M1.72M000
Gross Profit(1.12M)(1.72M)000
Gross Margin—————
Research & Development30.42M27.99M16.15M22.81M23.81M
Selling, General & Admin12.45M10.9M6.72M5.22M9.16M
Operating Expenses42.03M37.17M22.87M28.03M32.97M
Depreciation & Amortization1.12M1.72M1.82M1.62M1.62M
EBITDA(41.48M)(36.37M)(20.26M)(25.83M)(31.86M)
EBITDA Margin—————
Operating Income(43.15M)(38.89M)(22.87M)(28.03M)(32.97M)
Operating Margin—————
Interest Income468K267K548K442K0
Interest Expense01.34M1.71M1.53M685K
Other Income / Expenses544K(540K)(929K)(951K)(1.2M)
Income Before Tax(42.6M)(39.43M)(23.8M)(28.98M)(34.16M)
Pre-Tax Margin—————
Income Tax Expense0129K69K42K5K
Net Income(40.71M)(39.53M)(23.87M)(29.02M)(34.17M)
Net Margin—————
EPS (Basic)(67.80)(61.20)(16.99)(4.91)(2.09)
EPS (Diluted)(67.80)(61.20)(16.99)(4.91)(2.09)
Weighted Avg Shares1.25M1.3M1.4M5.91M16.35M
Weighted Avg Shares (Diluted)1.25M1.3M1.4M5.91M16.35M

PolyPid Ltd.

NASDAQ:PYPD

Intrinsic Alpha fair value

Locked

Current Price

$6.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.